FibroGen founder Neff dies suddenly as drug he championed racks up milestones

FiercePharma | August 26, 2019

After founding FibroGen in 1993 and leading the company for 26 years, chairman and CEO Thomas B. Neff passed away over the weekend unexpectedly. His death comes as FibroGen nears the critical U.S. and European filings for its Astellas- and AstraZeneca-partnered oral anemia med roxadustat, which recently won its second approval in China. With Neffs death, FibroGen has appointed 9-year board member James Schoeneck as its interim CEO. The company is seeking a world-class replacement to take the helm. Neff leaves a legacy of innovation and dedication that has been rarely matched in this industry, FibroGens board said in a statement. He founded the company in 1993 and his work led to the development of roxadustat and pamrevlumab, which is in testing for fibrosis and associated diseases. “The board of directors, management team, and employees, deeply mourn his passing, and extend our heartfelt sympathy and condolences to his family,” the statement added. Monday’s sad news comes right on the heels of roxadustat’s second approval in China for anemia patients not on dialysis. The drug won an approval there last December for anemia in dialysis patients, its first in the world.

Spotlight

Globally, pharmaceutical regulators are becoming attuned to cold chain issues as biologics, vaccines, and other
temperature‐sensitive products are commercialized for a global clientele. Many regulators now recommend including
temperature monitoring technology in every cold chain shipment.

Spotlight

Globally, pharmaceutical regulators are becoming attuned to cold chain issues as biologics, vaccines, and other
temperature‐sensitive products are commercialized for a global clientele. Many regulators now recommend including
temperature monitoring technology in every cold chain shipment.

Related News

BUSINESS INSIGHTS, PHARMACY MARKET

PCI Pharma Services Announces New Sterile Fill-Finish Capabilities Now Available in Melbourne and San Diego

Businesswire | April 24, 2023

PCI Pharma Services a leading global contract development and manufacturing organization announced that three new state-of-the-art automated sterile fill-finish machines at its San Diego and Melbourne facilities are now fully operational. The innovative machinery from Cytiva can be used to fill various sterile medications into vials and syringes for small-to-mid scale client needs. The equipment, paired with PCI’s end-to-end services, accelerates Speed to Study™, and drastically decreases the average turnaround time from proposal signing to the injectable product’s distribution. “As the capacity for CDMOs worldwide to take on new projects shrinks, we’re excited to be able to offer integrated sterile fill-finish capabilities, alongside our clinical packaging facilities, to new and existing clients in Melbourne and San Diego,” said Brad Payne, Chief Operating Officer, PCI Pharma Services. “Our increased capacity, stockpile of standardized components, including glass, and technical expertise means we can start running batches as soon as needed. This will cut down on the wait times many pharmaceutical companies are facing and begin to help alleviate the global capacity shortage for sterile drug product and downstream packaging.” The Microcell Vial Filler and SA25 Aseptic Filling Workcell at PCI’s San Diego facility ensures the delivery of medicines from phase I through phase III, supporting local and global Clinical client needs. Additionally, a Microcell Vial Filler at Melbourne further enhances the early-stage services offered and brings additional capacity to Australia—the world’s leading phase I environment. These advanced machines expedite the filling process with automation and remove the need for human intervention in a sterile environment, creating compliance advantages over standard equipment. “There are less barriers to entry to start a clinical trial in Australia, as well as significant cost benefits, and with Melbourne being an especially popular place to conduct phase I trials, we knew we needed to bring this capability and added capacity to the local market,” said Tim Roberts, Chief Commercial Officer, PCI Pharma Services. “In addition, we are then able to take our clients through their lifecycle journeys with the expansions and advanced capabilities in our New Hampshire and Madison campuses. With successful recent inspections at our Bedford facility by the Brazilian (ANVISA) and Japanese (PDMA) regulatory authorities, our global reach to supply life-changing therapies to patients quickly and safely is wider than before.” To better support its clients throughout the world, PCI has also recently invested in expansions in Rockford, IL, and Tredegar, Wales, as well as established new facilities in Bedford, NH, and Bridgewater, MA. About PCI Pharma Services PCI is a leading global CDMO, providing clients with integrated end-to-end drug development, manufacturing and packaging capabilities that increase their products’ speed to market and opportunities for commercial success. PCI brings proven experience that comes with more than 50 successful product launches each year and over five decades in the healthcare services business. We currently have 30 sites across seven countries (Australia, Canada, U.S., Ireland, Wales, Germany and Spain) and over 4,300 employees that work to bring life-changing therapies to patients. Leading technology and continued investment enable us to address global drug development needs throughout the entire product life cycle – from manufacturing capabilities through the clinical trial supply chain and into commercialization. Our clients view us as an extension of their business and a collaborative partner with the shared goal of improving patients’ lives.

Read More

BUSINESS INSIGHTS, PHARMACY MARKET

Patsnap Unveils Synapse Visitor, the Latest AI-Powered Pharmaceutical Intelligence Platform

Prnewswire | April 25, 2023

On April 20, Patsnap, the world's leading SaaS provider for intelligence, announced the launch of its latest version of the intelligence platform, Synapse, available to visitors. This version includes advanced search functions for drugs and pharmaceutical organizations, now publicly accessible for the first time. Users can explore these features without prior registration, making searching easier and more accessible than ever before. Synapse is an innovative Life Sciences Platform that uses AI technology to connect Drug Discovery information with Drug Development insights. This allows professionals in the pharmaceutical industry to make better-informed decisions throughout the entire innovation cycle. With a vast database of millions of free data points from over 150 jurisdictions, Synapse provides access to over 72,000 new drugs, 800,000 clinical trials, 6 million pharmaceutical patents, 62 million literature sources, 360,000 pharmaceutical organizations, and more. This wealth of information is available to users to aid them in their research and decision-making processes. One of the key benefits of Synapse is its extensive database of drugs, particularly those in their preclinical or early developmental stages, which helps to mitigate potential risks for professionals in the pharmaceutical industry. "We want to ensure that we are only developing drugs that are efficiently managed, reducing the risks of failure at the later stages of development," said one of our key clients, the head of R&D. By having access to this valuable information, professionals can make more informed decisions and focus their efforts on drugs with a higher potential for success, ultimately saving time and resources. Available on Synapse's website as a free solution, key features include Drug Advanced Search:Quickly and accurately identify drugs based on specific criteria of interest. The search function covers global drug candidates and marketed drugs, and mines preclinical R&D intelligence in patents and literature to identify early competitive risks. Clinical Progress:Screen clinical trials by drugs, institutions, targets (multi-target), indications, clinical trial phase, and other conditions. Synapse collates data from 18 registries, including CT.gov and WHO, giving users a global view of the clinical landscape. Playbook: Access multiple data sets with a single search, including Due Diligence and Find Organizations. This feature provides comprehensive and visualized insights into the organization's R&D preferences, drug pipeline, investments, financing, and more. Literature Search:With over 62 million literature records in the life sciences field, users can easily screen literature by drugs, targets, indications, authors, and other criteria. This feature allows for efficient and targeted research, saving time and increasing productivity. About Patsnap Founded in 2007, Patsnap is the company behind the world's leading AI-powered innovation intelligence platform. Patsnap provides global businesses with a connected, easy-to-use platform that helps them make better decisions in the innovation process. Customers are innovators across multiple industry sectors, including agriculture and chemicals, consumer goods, food and beverage, life sciences, automotive, oil and gas, professional services, aviation and aerospace, and education.

Read More

PHARMACY MARKET

Mednow Announces Partnership With Medcan Health Management Inc. to Deliver Collaborative, Interdisciplinary Healthcare

businesswire | May 18, 2023

Mednow Inc Canada’s on-demand virtual pharmacy has been named the preferred virtual pharmacy partner for Medcan Health Management Inc. and its valued clients. Mednow is focused on improving the delivery of pharmacy services in Canada through digitization to provide better patient access to pharmacists, doctors and other healthcare professionals. Mednow offers instant access to pharmacists in the Mednow app or on the phone and offers fast, free delivery of prescription medication. “At Medcan, we’re always striving to bring our valued clients the highest level of service and incredible level of care through integrated, comprehensive and convenient health and wellness services, including ensuring they have easy access to a premium pharmacy experience,” said Shaun Francis, CEO and Chair of Medcan. “By partnering with Mednow, our Medcan clients will not only have a new option to get their prescription medications, over the counter products or supplements, but also the added benefit of always-on access to knowledgeable pharmacists who can help ensure they’re taking medications correctly,” said Francis. “Mednow is proud to partner with Medcan, a pioneer in high quality healthcare in Canada and an ideal partner to work with to reduce care fragmentation and enhance collaboration between our two healthcare professions,” said Ali Reyhany, CEO and Co-Founder of Mednow. “Our proprietary technology provides seamless access to our pharmacy team, which deploys the latest health technologies and best practices in pharmacy to optimize patient care. Texting your pharmacist, automatic refill reminders and the availability of Pillsmart™ medication packs are just some of the ways Mednow can help Medcan’s mutual patients,” said Reyhany. About Mednow Mednow is a healthcare technology company offering virtual access with a high-standard of care. Designed with accessibility and quality of care in mind, Mednow provides virtual pharmacy and telemedicine services as well as doctor home visits through an interdisciplinary approach to healthcare that is focused on the patient experience. Mednow’s services include free at-home delivery of medications, doctor consultations, a user- friendly interface for easy upload, transfer, and refill of prescriptions, access to healthcare professionals through an intuitive chat experience and the specialized PillSmart™ system that packages prescriptions in easy-to-use daily dose packs, each labelled with the date and time of the next dose.

Read More